Advanced therapy medicinal products
Ugeskrift for Læger · 2026
DOI: 10.61409/v12251027 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ugeskrift for Læger, 2026. Verfasst von Rasmus Roost Aabling und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institut for Klinisk Medicin, Comparative Medicine Lab, Aarhus Universitet. Hauptthemen laut MEDLINE: Genetic Therapy. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Advanced therapy medicinal products are a rapidly expanding drug class based on genes, cells, and tissues, transforming the treatment of diseases, including haematologic cancers and genetic disorders, such as sickle cell disease and haemophilia. This review highlights that successful clinical implementation requires coordinated national strategies, regulatory support, sustainable funding, robust clinical and production infrastructure, and trained specialised personnel to ensure timely, safe, and equitable patient access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institut for Klinisk Medicin, Comparative Medicine Lab, Aarhus Universitet.
- Institut for Klinisk Medicin, SDCA-Steno Diabetes Center Aarhus, Aarhus Universitet.
- Ortopædkirurgisk Afsnit, Center for Planlagt Kirurgi, Regionshospitalet Silkeborg.
- Center for Gen- og Celleterapi, Blodbank og Immunologi, Aarhus Universitetshospital.
- Molekylær Medicinsk Afdeling (MOMA), Aarhus Universitetshospital.
- Klinisk Farmakologi, Aarhus Universitetshospital.
Zitieren
APA
Aabling, R. R., Revenfeld, A. L. S., & Rusan, M. (2026). Advanced therapy medicinal products. Ugeskrift for Læger. https://doi.org/10.61409/v12251027
Vancouver
Aabling RR, Revenfeld ALS, Rusan M. Advanced therapy medicinal products. Ugeskrift for Læger. 2026. doi:10.61409/v12251027
BibTeX
@article{Aabling2026,
author = {Aabling, Rasmus Roost and Revenfeld, Anne Louise Schacht and Rusan, Maria},
title = {Advanced therapy medicinal products},
journal = {Ugeskrift for Læger},
year = {2026},
doi = {10.61409/v12251027}
}
EUVIMED